|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0031082,
umls-concept:C0087111,
umls-concept:C0229664,
umls-concept:C0242485,
umls-concept:C1504389,
umls-concept:C1515895,
umls-concept:C1516084,
umls-concept:C1519595,
umls-concept:C1546856,
umls-concept:C1977882
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-5-4
|
|
pubmed:abstractText |
We identified 243 patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) who had BCR-ABL transcripts monitored by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) after allogeneic stem cell transplantation for a median of 84.3 months. Individual patients were regarded as having achieved molecular relapse (MR) if the BCR-ABL/ABL ratio exceeded 0.02% on 3 occasions or reached 0.05% on 2 occasions. Patients were allocated to 1 of 4 categories: (1) 36 patients were "persistently negative" or had a single low-level positive result; (2) 51 patients, "fluctuating positive, low level," had more than 1 positive result but never more than 2 consecutive positive results; (3) 27 patients, "persistently positive, low level," had persisting low levels of BCR-ABL transcripts but never more than 3 consecutive positive results; and (4) 129 patients relapsed. In 107 of these, relapse was based initially only on molecular criteria; in 72 (67.3%) patients the leukemia progressed to cytogenetic or hematologic relapse either prior to or during treatment with donor lymphocyte infusions. We conclude that the pattern of BCR-ABL transcript levels after allograft is variable; only a minority of patients with fluctuating or persistent low levels of BCR-ABL transcripts satisfied our definitions of MR, whereas the majority of patients who did so were likely to progress further.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-10231146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-10607686,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-11023502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-11238091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-11736937,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-11919387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-12563612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-2338131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-2572849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-3510388,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-3511810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-4153799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-6125773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-7579468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-7632930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-7655033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-7727789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8193375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8289486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8338780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8400243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8639810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-8769690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-9053463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16449534-9266951
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:ApperleyJane FJF,
pubmed-author:CrossNicholas C PNC,
pubmed-author:DazziFrancescoF,
pubmed-author:GoldmanJohn MJM,
pubmed-author:KaedaJaspalJ,
pubmed-author:KhorashadJamshid SJS,
pubmed-author:MarinDavidD,
pubmed-author:O'SheaDervilleD,
pubmed-author:OlavarriaEduardoE,
pubmed-author:SaundersSusanS,
pubmed-author:SzydloRichard MRM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4171-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16449534-Adult,
pubmed-meshheading:16449534-Biological Markers,
pubmed-meshheading:16449534-Disease Progression,
pubmed-meshheading:16449534-Female,
pubmed-meshheading:16449534-Fusion Proteins, bcr-abl,
pubmed-meshheading:16449534-Humans,
pubmed-meshheading:16449534-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16449534-Male,
pubmed-meshheading:16449534-Stem Cell Transplantation,
pubmed-meshheading:16449534-Survivors,
pubmed-meshheading:16449534-Transcription, Genetic,
pubmed-meshheading:16449534-Transplantation, Homologous,
pubmed-meshheading:16449534-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
|
|
pubmed:affiliation |
Department of Haematology, Imperial College at Hammersmith Hospital, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
